Work Here?
Korro Bio
Work Here?
RNA editing-based therapeutics discovery and development
Korro Bio
Work Here?
RNA editing-based therapeutics discovery and development
About Korro Bio
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2019
Overview
Korro Bio develops RNA-based therapies using RNA editing to modify protein function, aiming to treat serious diseases with few or no current options. The approach targets RNA itself, enabling single base edits in transcripts to change how proteins work, which can adjust disease pathways without altering the DNA. These therapies are intended to be developed and brought to market through direct development or partnerships, with revenue coming from therapy sales, licensing, and collaborations. The company focuses on research and development to translate human genetics insights into treatments, working with healthcare providers, patients, and academic partners. Overall, Korro Bio seeks to move RNA editing toward real therapies that can help patients around the world by offering precise, targeted interventions at the RNA level.
Simplify's Take
What believers are saying
- $85M PIPE in 2025 extends cash runway through H2 2028.
- Novo Nordisk partnership develops cardiometabolic candidates since Sept 2024.
- KRRO-121 advances for urea cycle disorders and hepatic encephalopathy.
What critics are saying
- KRRO-110 trial failed functional protein levels, causing 80% stock drop.
- Beam Therapeutics' base editing outpaces Korro in AATD liver delivery.
- Intellia CRISPR AATD enters Phase 1 with 50% NHP protein correction.
What makes Korro Bio unique
- OPERA platform co-opts endogenous ADAR for precise single-base RNA edits.
- CHORD oligonucleotides enable high specificity without off-target DNA risks.
- Targets liver diseases like AATD using precedented manufacturing and delivery.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$479.5M
Above
Industry Average
Funded Over
4 Rounds
New Enterprise AssociatesBenefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Retirement Plan
401(k) Company Match
Company Equity
Stock Price
Growth & Insights and Company News
6 month growth
↑ 7%1 year growth
↑ 10%2 year growth
↑ 12%Korro Bio has raised $85 million through a private investment in public equity (PIPE) round led by new investor Bainrock Healthcare Capital Partners. The company issued 4.5 million ordinary shares at $11.11 per share and 3.1 million pre-funded warrants at $11.109 per share. Combined with $85.2 million in cash and cash equivalents as of 31 December 2025, the funding extends Korro Bio's cash runway through the second half of 2028. The capital will accelerate development of its RNA editing platform OPERA, including clinical programmes KRRO-121 and a GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin deficiency. Citigroup, Cantor, Oppenheimer and William Blair served as placement agents. Analysts forecast continued losses through 2027 despite projected revenue growth.
Korro Bio raises $85 million in private equity financing
Korro to present at the 43rd Annual J.P. Morgan Healthcare Conference.
In other recent news, Korro Bio has announced a strategic partnership with Novo Nordisk (NYSE:NVO), a global healthcare company, to develop genetic medicines for cardiometabolic diseases.
Korro Bio announces collaboration with Novo Nordisk to develop two therapeutic candidates.
Korro Bio is Hiring for 4 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Korro Bio
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2019
Korro Bio is Hiring for 4 Jobs on Simplify!
Find jobs on Simplify and start your career today